Review Article
The Diagnostic Power of Circulating miR-1246 in Screening Cancer: An Updated Meta-analysis
Table 1
Characteristics of included studies.
| Author | Year | Country | Case vs. control | Clinical stage | , case/control | Sample | Technique | TP | FP | TN | FN | AUC | Ref. |
| Takeshita | 2013 | Japan | ESCC vs. HC | I-IV | 101/46 | Serum exosome | RT-qPCR | 72 | 12 | 34 | 29 | 0.754 | [19] | Ogata-Kawata | 2014 | Japan | CRC vs. HC | I-IV | 88/11 | Serum exosome | Microarray | 84 | 1 | 10 | 4 | 0.948 | [20] | Fu | 2016 | China | BC vs. HC | I-IV | 100/40 | Serum | RT-qPCR | 93 | 10 | 30 | 7 | 0.904 | [21] | Armand-Labit | 2016 | France | Melanoma vs. HC | III-IV | 28/16 | Plasma | RT-qPCR | 26 | 1 | 15 | 2 | 0.95£ | [22] | Chai | 2016 | Hong Kong | HCC vs. HC | Na | 61/24 | Plasma | RT-qPCR | 49 | 0 | 24 | 12 | 0.982£ | [23] | Hannafon | 2016 | USA | BC vs. HC | 0-III | 16/16 | Plasma exosome | RT-qPCR | 9 | 1 | 15 | 7 | 0.69£ | [24] | Machida | 2016 | Japan | PT vs. HC | I-IV | 12/13 | Saliva exosome | RT-qPCR | 8 | 0 | 13 | 4 | 0.814 | [25] | Shimomura | 2016 | Japan | BC vs. HC | 0-IV | 1206/1397 | Serum | Microarray | 1065 | 92 | 1305 | 141 | 0.91 | [26] | Xu | 2017 | USA | PC vs. HC | I-IIA | 15/15 | Plasma exosome | RT-qPCR | 10 | 3 | 12 | 5 | 0.73£ | [27] | Todeschini | 2017 | Italy | OC vs. HC | III-IV | 168/65 | Serum | RT-qPCR | 146 | 15 | 50 | 22 | 0.893 | [28] | Zhai | 2018 | China | BC vs. HC | Na | 46/28 | Plasma exosome | Au nanoflare probe | 46 | 2 | 26 | 0 | 0.982 | [29] | Bhagirath | 2018† | USA | PCa vs. HC | IV | 44/8 | Serum exosome | RT-qPCR | 33 | 0 | 8 | 11 | 0.926 | [30] | Bhagirath | 2018‡ | USA | PCa vs. HC | IV | 43/7 | Serum exosome | RT-qPCR | 38 | 0 | 7 | 5 | 0.933 | [30] | Moshiri | 2018 | Italy | HCC vs. cirrhosis | Na | 16/27 | Plasma | ddPCR | 14 | 4 | 23 | 2 | 0.97 | [31] | Wang | 2018 | China | HCC vs. HC | I-IV | 50/50 | Serum exosome | RT-qPCR | 30 | 6 | 44 | 20 | 0.825£ | [32] | Guo | 2018 | China | CRC vs. HC | 0-IV | 107/120 | Serum | RT-qPCR | 69 | 38 | 82 | 38 | 0.681 | [33] | Shi | 2020 | China | GC vs. HC | I-IV | 85/50 | Serum exosome | RT-qPCR | 70 | 7 | 43 | 15 | 0.911 | [34] | Wei | 2020 | China | PC vs. benign+HC | I-IV | 120/80 | Serum | RT-qPCR | 101 | 29 | 51 | 19 | 0.81 | [35] | Ishige | 2020 | Japan | PC vs. HC | 0-IV | 41/30 | Serum | RT-qPCR | 38 | 8 | 22 | 3 | 0.87 | [36] | Salah | 2020 | Egypt | CRC vs. HC | II-III | 37/30 | Serum | RT-qPCR | 37 | 6 | 24 | 0 | 0.924 | [37] | Huang | 2020 | China | NSCLC vs. HC | I | 33/50 | Serum | RT-qPCR | 21 | 7 | 43 | 12 | 0.827£ | [38] | Hoshino | 2020† | Japan | ESCC vs. HC | I-IV | 55/39 | Serum | RT-qPCR | 40 | 12 | 27 | 15 | 0.816 | [39] | Hoshino | 2020‡ | Japan | ESCC vs. HC | I-IV | 101/34 | Serum | RT-qPCR | 72 | 10 | 24 | 29 | 0.779 | [39] | Ueta | 2021 | Japan | GBC vs. benign+HC | 0-IV | 50/69 | Serum exosome | RT-qPCR | 30 | 23 | 46 | 20 | 0.646 | [40] | Chen | 2021 | China | BC vs. HC | Na | 33/37 | Plasma exosome | Molecular beacon | 31 | 1 | 36 | 2 | 0.983 | [41] | Zhang | 2021 | China | BC vs. HC | I-IV | 21/9 | Plasma exosome | Electrochemical biosensor | 17 | 0 | 9 | 4 | 0.931£ | [42] | Chen | 2021 | China | HCC vs. HC | I-IV | 50/50 | Serum | RT-qPCR | 41 | 10 | 40 | 9 | 0.865 | [43] | Jang | 2021† | Korea | BC vs. HC | 0-IV | 146/90 | Serum | RT-qPCR | 136 | 13 | 77 | 10 | 0.955 | [44] | Jang | 2021‡ | Korea | BC vs. HC | 0-IV | 80/56 | Plasma | RT-qPCR | 77 | 8 | 48 | 3 | 0.963 | [44] | Hoshino | 2021§ | Japan | ESCC vs. HC | I-IV | 72/50 | Urine | RT-qPCR | 65 | 19 | 31 | 7 | 0.823 | [45] | Hoshino | 2021¶ | Japan | ESCC vs. HC | I-IV | 72/50 | Saliva | RT-qPCR | 60 | 17 | 33 | 12 | 0.802 | [45] | Rafiee | 2022 | Iran | CRC vs. HC | I-III | 45/45 | Serum | RT-qPCR | 27 | 1 | 44 | 18 | 0.84£ | [46] | Zhao | 2022 | China | MM vs. HC | I-III | 90/30 | Serum | RT-qPCR | 78 | 1 | 29 | 12 | 0.952 | [47] |
|
|
AUC: area under the receiver operating characteristic (ROC) curve; BC: breast cancer; CRC: colorectal cancer; ESCC: esophageal squamous cell carcinoma; GBC: gallbladder cancer; GC: gastric cancer; HC: healthy control; HCC: hepatocellular carcinoma; MM: multiple myeloma; Na: not available; NSCLC: non-small-cell lung cancer; OC: ovarian cancer; PC: pancreatic cancer; PCa: prostate cancer; PT: pancreatobiliary tract cancer; ddPCR: droplet digital polymerase chain reaction; RT-qPCR: reverse transcriptase quantitative polymerase chain reaction; TP: true positive; FP: false positive; TN: true negative; FN: false negative; Ref.: reference. †Test set. ‡Validation set. §Testing in urine specimens. ¶Testing in saliva specimens. £Sensitivity and specificity values corresponding to the maximum Youden’s index were extracted from the ROC curve; then, true positive, false positive, true negative, and false negative numbers were calculated. |